Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;27(1):e1-e8.
doi: 10.3747/co.27.5211. Epub 2020 Feb 1.

Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study

S Shakeel  1 , C Finley  2 , G Akhtar-Danesh  2 , H Y Seow  3   4 , N Akhtar-Danesh  3   5
Affiliations

Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study

S Shakeel et al. Curr Oncol. 2020 Feb.

Abstract

Background: Pancreatic cancer (pcc) is one of the most lethal types of cancer, and surgery remains the optimal treatment modality for patients with resectable tumours. The objective of the present study was to examine and compare trends in the survival rate based on treatment modality in patients with pcc.

Methods: This population-based retrospective analysis included all patients with known-stage pcc in Ontario between 2007 and 2015. Flexible parametric models were used to conduct the survival analysis. Survival rates were calculated based on treatment modality, while adjusting for patient- and tumour-specific covariates.

Results: The study included 6437 patients. We found no noticeable improvement in survival for patients with stage iii or iv tumours; however, for stage i disease, the 1-, 2-, and 5-year survival rates increased over time to 81% from 51%, to 71% from 35%, and to 61% from 22% respectively. Most improvements were seen for surgical modalities, with 2-year survivals increasing to 89% from 65% for distal pancreatectomy (dp) without radiation (rt) or chemotherapy (ctx), to 65% from 37% for dp plus rt or ctx, to 60% from 44% for Whipple-only, and to 50% from 36% for Whipple plus rt or ctx. Lastly, 5-year survival improved to 81% from 52% for dp only, to 41% from 12% for dp plus rt or ctx, to 49% from 25% for Whipple-only, and to 26% from 12% for Whipple plus rt or ctx.

Conclusions: Most cases of pcc continue to be diagnosed at a late stage, with poor short-term and long-term prognoses. After adjustment for patient age, sex, and year of diagnosis, the survival for stage i tumours and for surgical modalities increased over time. Further research is needed to identify the reasons for improvement in survival during the study period.

Keywords: Pancreatic cancer; survival trends; treatment modalities.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

Figures

FIGURE 1
FIGURE 1
Trends in overall 1-, 2-, and 5-year survival rates adjusted for age, sex, disease stage, and treatment modality from 2007 to 2015.
FIGURE 2
FIGURE 2
Adjusted trends in 1-year, 2-year, and 5-year survival rates from 2007 to 2015, based on treatment modality. RT = radiation therapy; CT = chemotherapy; DP = distal pancreatectomy.
FIGURE 3
FIGURE 3
Adjusted trends in 1-year, 2-year, and 5-year survival rates from 2007 to 2015, based on age group and sex.
FIGURE 4
FIGURE 4
Adjusted trends in 1-year, 2-year, and 5-year survival rates from 2007 to 2015, based on stage of disease.
See this image and copyright information in PMC

References

    1. Ellison L. Age-Specific Patterns in the Incidence of, and Survival from, Pancreatic Cancer in Canada. Ottawa, ON: Statistics Canada; 2017.
    1. Collier R. Half of Canadians can expect cancer diagnosis during lifetime. CMAJ. 2017;189:E920. doi: 10.1503/cmaj.1095447. - DOI - PMC - PubMed
    1. American Cancer Society (acs) Cancer Facts and Figures 2017. Atlanta, GA: ACS; 2017.
    1. Padbury RT. Survival from pancreatic cancer: it’s not just about the surgical mortality. Med J Aust. 2012;196:491–2. doi: 10.5694/mja12.10545. - DOI - PubMed
    1. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013;144:1316–26. doi: 10.1053/j.gastro.2013.01.078. - DOI - PubMed

Publication types

LinkOut - more resources